Abbott Receives FDA Emergency Use Authorization For COVID-19 Antibody Blood Test

Abbott announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company's SARS-CoV-2 IgG lab-based serology blood test on the Alinity™ i system. Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT® and Alinity i platforms and will have capacity for 60 million tests in June.

Abbott received FDA EUA and CE Mark for its SARS-CoV-2 IgG antibody blood test on the ARCHITECT system. Abbott has already begun shipping antibody tests for use on the ARCHITECT systems globally including in the . . .